myExtraContent1
myExtraContent5

Oct 2015

First patient treated. VPM1002BC: New treatment option for patients with recurrent bladder cancer

A clinical phase I/II trial has started recently in Basel, Switzerland, investigating the drug VPM1002BC in patients suffering from recurrent bladder cancer that became unresponsive to standard therapy. The trial SAKK 06/14 will be conducted at 8 centers throughout Switzerland, Germany, and The Netherlands.

For the complete press release please click here

8th International VPM Days - presentations online

8th International VPM Days
“Translational Development - From Target to Market”
17.-18. September 2015
im TWINCORE in Hannover


We thank all speakers who accepted our invitation to share their experience with us at the „8th International VPM Days“ in Hannover. Like the years before we are happy to provide the conference presentations online.


Thursday September 17th, 2015

13.00 – 13.30
Welcome & opening remarks
Dr. Bernd Eisele (VPM) & Marina Lerch (hannoverimpuls)

Key Note Lecture:
13.30 – 14.00 Dr. Jan Langermans (Biomedical Primate Research Centre)
“Large animal models for vaccine development”


Session 1: Translational Research & Development – Academia Perspective
14.00 – 14.20 Dr. Cyrill Rentsch (Universitätsspital Basel)
“Immune Therapy in Bladder Cancer”

14.20 – 14.40 Dr. Jens Peter Horn (medac GmbH)
„BCG in Bladder Cancer“

15.00 – 15.20 Dr. Christoph Conrad (Paul-Ehrlich-Institut)
“Advantages of an Early Scientific Advice Meeting”

15.20 – 15.40 Prof. Dr. Christoph Schindler (CRC) “Drug discovery and the pharmaceutical ecosystem – the evolving role of academic drug development”

15.40 – 16.00 Dr. Florence Bietrix (EATRIS ERIC)
„EATRIS ERIC, European Infrastructure for Translational Medicine “



Session 2: Start-Up Perspective
16.20 – 16.40 Dr. Karsten Fischer (BioMedPartners)
“Venture financed Innovation“

16.40 – 17.00 Max Ostermeier (Implandata Ophthalmic Products GmbH)
"Critical factors for a Start-Up in developing disruptive medical devices"

17.00 – 17.20 Thomas Grutzeck (Peer Boards Deutschland GmbH & CO. KG)
“Peer CEO Advisory Boards – Shared Experience for Bottom Line Success“

17.20 – 17.40 Dr. Maike Rochon (BioRegioN)
“Life Sciences in Lower Saxony”

17.40 – 18.00 Dr. Alexander Werner (ImevaX)
“Translational Development of IMX101 – a best practice model “



Friday September 18th, 2015


Session 3: Pharma Perspective
09.00 – 09.20 Dr. Karen Götz (Paul-Ehrlich-Institut)
“Challenge Studies for Vaccines”  

09.20 – 09.40 Victor Strugo (Triclinium)
“A current perspective on the clinical research opportunities and challenges in South Africa and neighbouring countries”

09.40 – 10.00 Dr. Lorenzo Tolleri (GlaxoSmithKline) “Due Diligence – how big pharma analyses data and evaluates licensing opportunities“

10.00 – 10.20 Dr. Florentine Radelfahr (Wellington Partners)
“What makes a good business plan - the VC perspective”

10.20 – 10.40 Prof. Dr. Ulrich Kalinke (TWINCORE)
„Current news from TRAIN, the translational alliance in the Braunschweig – Hannover region”


Session 4: Legal / IP & Finance
11.00 –11.20 Dr. Wolfgang Weiß (Weickmann & Weickmann)
"IP Strategy for Start-Up Companies in the Pharma/Biotech-Field"

11.20 – 11.40 Piet Weinreich (Osborne Clarke)
“Legal traps in technology transfers – an appraisal of the European antitrust regime”

11.40 – 12.00 Robert Simmons (ZAB Brandenburg)
„Digital Health - A Paradigm Change“

12.00 – 12.20 Dr. Christian A. Stein (Ascenion GmbH)
„Just licensing is not enough“

12.20 – 12.40 Dr. Umesh Shaligram (Serum Institute of India)
“Translational Development – Strategies for Global Reach “

12.40 – 13.00 Closing remarks
Dr. Bernd Eisele (VPM)
“Be fast – be good – or be gone”


For additional information please contact:

Christoph Schütz
Conference Manager
Tel: +49 511 169908-19
Fax: +49 511 169908-29
info@vakzine-manager.de


myExtraContent7
myExtraContent8